-+ 0.00%
-+ 0.00%
-+ 0.00%

ALX ONCOLOGY ANNOUNCES THAT CD47 BIOMARKER DATA FROM CLINICAL TRIAL EVALUATING EVORPACEPT + ZANIDATAMAB COMBINATION IN ADVANCED BREAST CANCER WILL BE PRESENTED AT ESMO BREAST CANCER 2026

Reuters·04/30/2026 12:00:03

Please log in to view news